Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Buy” from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.60.

SANA has been the subject of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday. Jefferies Financial Group started coverage on Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 price target for the company. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research report on Thursday, April 24th.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its stake in shares of Sana Biotechnology by 5.4% during the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after acquiring an additional 9,359 shares in the last quarter. SCS Capital Management LLC acquired a new position in Sana Biotechnology during the first quarter worth $137,000. Woodline Partners LP boosted its position in Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after purchasing an additional 90,515 shares in the last quarter. Clearline Capital LP acquired a new stake in Sana Biotechnology in the first quarter valued at $690,000. Finally, AQR Capital Management LLC grew its holdings in Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after purchasing an additional 190,483 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $2.87 on Friday. The stock has a fifty day moving average price of $2.17 and a 200 day moving average price of $2.35. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.40. The company has a market cap of $647.13 million, a PE ratio of -3.26 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.